Akeso reveals survival data for Keytruda-beating cancer drug
Akeso Biopharma won first-line approval in China for its lung cancer drug ivonescimab, a new immunotherapy that it believes will top Merck's megablockbuster PD-L1 drug. As part of the approval, the company disclosed the additional ...
Akeso Biopharma won first-line approval in China for its lung cancer drug ivonescimab, a new immunotherapy that it believes will top Merck's megablockbuster PD-L1 drug.
As part of the approval, the company disclosed the additional ...
